AXL in metastatic ovarian cancer tumors is a targetable biomarker associated with chemoresistance and poor prognosis
Mullen, M.M., Quinn, J.M., Greenwade, M., Opara, G., Beck-Noia, H., Hagemann, I.S., Hagemann, A.R., Kuroki, L.M., McCourt, C.K., Thaker, P.H., Powell, M.A., Mutch, D.G., Fuh, K.C.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article
Therapeutic AXL inhibition of tumor and tumor microenvironment stromal cells improves response to chemotherapy in ovarian cancer
Mullen, M.M., Lomonosova, E., Beck-Noia, H., Wilke, D., Guo, L., Hagemann, A.R., Kuroki, L.M., McCourt, C.K., Thaker, P.H., Mutch, D.G., Powell, M.A., Fuh, K.C.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article